The prostamide‐related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias

    October 2012 in “The FASEB Journal
    Karzan Ghafur Khidhir, David F. Woodward, Nilofer Farjo, Bessam Farjo, Elaine S.‐H. Tang, Jenny W. Wang, Steven M. Picksley, Valerie A. Randall
    Image of study
    TLDR Bimatoprost, a glaucoma medication, may also help treat hair loss.
    The 2012 study investigated bimatoprost, a prostamide F2α analog used in glaucoma therapy, for its potential to treat scalp alopecias. It was found to stimulate hair growth in human scalp follicles in culture and in mice in vivo. Bimatoprost increased hair synthesis, prolonged the anagen phase, and advanced hair regrowth, with effects being receptor-mediated as confirmed by the blocking action of a prostamide receptor antagonist. Human scalp follicles were shown to express prostanoid receptor genes, indicating a potential for response to bimatoprost treatment. The study involved human scalp samples from 15 men and 2 women, molecular biological investigations of samples from 7 men and 1 woman, and immunohistochemical investigations involving 3 men and 2 women. Additionally, at least 6 hair follicles from each individual were used for each condition in the culture experiments, and the mouse study showed a significant reduction in the time to enter the anagen phase with bimatoprost treatment. The study concluded that bimatoprost could be a novel, low-risk therapeutic approach for treating scalp alopecias.
    View this study on onlinelibrary.wiley.com →

    Cited in this study

    Related